# OnCo record egfr-mutation-subtypes (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/egfr-mutation-subtypes/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "egfr-mutation-subtypes" ;
  schema:name "EGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M)"@en ;
  schema:alternateName "EGFR-mutant"@en, "EGFR-mutated"@en, "EGFR mutation"@en, "EGFR mutations"@en, "EGFR-positive"@en, "exon 19 deletion"@en, "exon 19 del"@en, "ex19del"@en, "L858R"@en, "exon 20 insertion"@en, "exon 20 ins"@en, "ex20ins"@en, "T790M"@en, "C797S"@en, "uncommon EGFR mutations"@en, "G719X"@en, "S768I"@en, "L861Q"@en, "EGFR-TKI"@en, "EGFR TKI"@en, "EGFR inhibitor"@en, "EGFR inhibitors"@en ;
  schema:description "Lung cancers with a mutated EGFR gene are treated with EGFR pills, but which pill and how well it works depends on exactly where the mutation is. Exon 19 deletions and L858R are the 'classic' sensitive ones; exon 20 insertions resist most pills; T790M and C797S appear when resistance develops."@en ;
  schema:url <https://onco.cc/terms/egfr-mutation-subtypes/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor> ;
  schema:citation <https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor> ;
  onco:related <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/gatekeeper-mutation/>, <https://onco.cc/terms/tki-term/>, <https://onco.cc/terms/cfdna/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/gefitinib/>, <https://onco.cc/drugs/erlotinib/>, <https://onco.cc/drugs/afatinib/>, <https://onco.cc/drugs/sunvozertinib/> ;
  onco:trials <https://onco.cc/trials/adaura/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-chen-east-asian-lung-adenocarcinoma-nat-genet-2020/>, <https://onco.cc/key-papers/paper-zhang-lung-cancer-never-smokers-nat-genet-2021/>, <https://onco.cc/key-papers/paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018/>, <https://onco.cc/key-papers/paper-lindeman-lung-molecular-testing-guideline-jto-2018/> .
